Ixekizumab in the treatment of psoriatic arthritis.

Abstract

Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic agents. IL-17 is at the heart and a critical factor in the onset of PsA. Ixekizumab, a high-affinity monoclonal antibody against IL-17 A, has been approved by the US FDA in March 2016 for baseline psoriasis and Dec 2017 for PsA; by the EMA in April 2016 and January 2018, respectively. This article reviews the published data relating to ixekizumab efficacy and safety in the PsA treatment.

• Authors: Eric Lespessailles, Hechmi Toumi
• Journal: Immunotherapy (Immunotherapy) Vol. 13 Issue 1 Pg. 19-33 (01 2021) ISSN: 1750-7448 [Electronic] England
• PMID: 33167745 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Dermatologic Agents
• ixekizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Arthritis, Psoriatic (drug therapy)
• Dermatologic Agents (therapeutic use)
• Humans
• Severity of Illness Index
• Treatment Outcome